Myriad Genetics (MYGN) said Monday that it "strongly disagrees" with UnitedHealthcare's decision to restrict coverage access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under the commercial and individual exchange benefit plans.
The updated policy, which takes effect on Jan. 1, is based on the rationale that there is insufficient evidence of efficacy to support coverage of GeneSight, according to the company.
Myriad said it is working with UnitedHealthcare to discuss the clinical evidence for GeneSight and get continued coverage access for the test.
UnitedHealthcare did not immediately respond to MT Newswires' request for comment.
Myriad Genetics' shares were down more than 3% in recent trading.
Price: 17.39, Change: -0.60, Percent Change: -3.34
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.